Transcend Therapeutics

Transcend Therapeutics

Biotechnology, 220 5th Ave 17, New York, 10001, United States, 1-10 Employees

transcendtherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: +12*********

Who is TRANSCEND THERAPEUTICS

Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that ...

Read More

map
  • 220 5th Ave 17, New York, New York, 10001, United States Headquarters: 220 5th Ave 17, New York, New York, 10001, United States
  • 2021 Date Founded: 2021
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from TRANSCEND THERAPEUTICS

Transcend Therapeutics Org Chart and Mapping

Employees

Stephanie Galinos

Senior Clinical Trial Associate

Martin Stogniew

Chief Development Officer

Amanda Jones

Sr. Vice President, Clinical Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Transcend Therapeutics

Answer: Transcend Therapeutics's headquarters are located at 220 5th Ave 17, New York, 10001, United States

Answer: Transcend Therapeutics's phone number is +12*********

Answer: Transcend Therapeutics's official website is https://transcendtherapeutics.com

Answer: Transcend Therapeutics's revenue is $1 Million to $5 Million

Answer: Transcend Therapeutics has 1-10 employees

Answer: Transcend Therapeutics is in Biotechnology

Answer: Transcend Therapeutics contact info: Phone number: +12********* Website: https://transcendtherapeutics.com

Answer: Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications. Transcends leadership team includes the first scientist to receive federal funding for clinical psychedelic research in over 50 years and drug development executives with pivotal contributions to 13 FDA approvals, including the most recently approved drug for depression, and $7B dollars in M&A and public company value. Transcend has raised approximately $42M to date, and has been featured in the Wall Street Journal, Forbes, and Politico. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access